retatrutide release date UK 2026: Phase 3 Results 🎙️ NEW EPISODE: Retatrutide—The Triple

Retatrutide has cleared a large hurdle in TRANSCEND-T2D-1, the first phase III trial testing the triple hormone receptor agonist in patients with type 2 diabetes, according to new top-line results released today by Lilly

Like rash or redness, they typically go away on their own

the crude HR for hip fracture with GLP-1 RAs compared to DPP-4is was 0.68 [0.490.96], which was unaltered in the fully adjusted model (HR 0.65 [0.460.93])

Dixit AA, Bateman BT, Hawn MT, Odden MC, Sun EC

According to the American Diabetes Association , studies comparing GLP-1 medications have demonstrated significant weight loss potential for both semaglutide and tirzepatide